AGC Launches Innovative Fluoroelastomer Without the Use of Surfactants or Fluorinated Polymerization Solvents
AGC (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai)(TOKYO:5201), a world-leading manufacturer of glass, chemicals and other high-tech materials, proudly announces the launch of surfactant and fluorinated polymerization solvent free grades in its fluoroelastomer “AFLAS™ FFKM” series; the SF grades (the “Products”). The newly developed Products are manufactured entirely without the use of any surfactants*1 or fluorinated polymerization solvents*2. The Products offer high performance equivalent to that of conventional products, while meeting the growing market demand for fluoroelastomers that do not use surfactants or fluorinated polymerization solvents during the manufacturing process. This has been achieved through AGC’s innovative, proprietary polymer manufacturing technology (Surfactant-Free & Fluoro Solvent-Free Technology, hereafter the “Technology”). Initially, this Technology will be applied to the high-temperature-resistant type of FFKM fluoroelastomers and new grades will be added to the “AFLAS™ FFKM” series for semiconductor manufacturing equipment. Commercial availability of this new grade begins this month. We are planning to extend the Technology to other types of FFKM fluoroelastomers and will progressively introduce those new types of Products as part of “AFLAS™ FFKM” series.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717721155/en/
AFLAS(TM) FFKM Series Logo
The “AFLAS™ FFKM” series is an industrial elastomer that offers one of the highest levels of resistance to chemicals, heat, and plasma among fluoroelastomers. Its outstanding properties make it exceptionally durable even in harsh environments such as semiconductor manufacturing, oil drilling, and healthcare. In particular, “AFLAS™ FFKM” is recognized as an essential material in the etching process, one of the key steps in semiconductor manufacturing, due to its exceptional plasma resistance. Its resistance to degradation makes it an ideal sealing material for etching equipment, where it contributes to significantly extended maintenance intervals and enhanced operating safety.
Previously, surfactants and fluorinated polymerization solvents were considered essential for manufacturing high performance fluoroelastomers, FFKM, due to their roles in enhancing the reactivity of fluorinated monomers and manufacturing efficiency. In recent years, however, customers’ demand for products that do not use these substances during the manufacturing process have grown rapidly, particularly in the semiconductor industry. While various approaches without using surfactants or fluorinated polymerization solvents have been explored, achieving the high-performance requirements of FFKM was a significant challenge.
To meet this market demand, AGC has successfully overcome this long-standing technical challenge and succeeded in mass-production of the Products by applying the new Technology, which does not require the use of any type of surfactants or fluorinated polymerization solvents, which has been developed by refining our unique polymerization technology cultivated over many years. Accordingly, AGC is now proud to introduce the Products as new addition to its AFLAS™ FFKM series.
Under its corporate philosophy of “Look Beyond”, the AGC Group is committed to supporting the lives of people around the world through its unique materials and solutions. Going forward, we will continue to contribute to the realization of a safe, secure, and sustainable society through our high-performance, high-quality materials.
| Notes | |
*1 | surfactant: A chemical substance used to mix non-mixable substances and form a homogeneous mixture called an emulsion. Also called an emulsion. |
*2 | polymerization solvent: A solvent used to promote polymerization reactions. Various solvents are selected depending on the type and purpose of polymerization. In emulsion polymerization, water is generally used, while in solution polymerization, solvents that easily dissolve the polymerizable monomer are used. |
REFERENCE
Website of AFLAS™ FFKM series
View source version on businesswire.com: https://www.businesswire.com/news/home/20250717721155/en/
Contacts
MEDIA INQUIRIES
AGC Inc.
Corporate Communications & Investor Relations Division
Contact: info-pr(at)agc.com
Product inquires
AGC Inc.
Chemicals Company Contact form:
https://www.agc-chemicals.com/jp/en/fluorine/inquiry/form.html?f_id=FLN-JP-EN-00
03 -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.agc-chemic
als.com%2Fjp%2Fen%2Ffluorine%2Finquiry%2Fform.html%3Ff_id%3DFLN-JP-EN-0003&eshee
t=54291312&newsitemid=20250717721155&lan=en-US&anchor=https%3A%2F%2Fwww.agc-chem
icals.com%2Fjp%2Fen%2Ffluorine%2Finquiry%2Fform.html%3Ff_id%3DFLN-JP-EN-0003&ind
ex=2&md5=5bc080873a6f3e000c82c5b99fd7c79f
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Sends Second Public Shareholder Letter to Coway, Urging Announcement of Revised Value-up Plan by January 30, 202615.12.2025 15:54:00 CET | Press Release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway”) since 2023 holding more than 4% of the Company’s outstanding shares through funds it manages or advises, announced that it has sent a second public shareholder letter to Coway’s Board of Directors. The letter calls for measures to address the company’s chronic undervaluation and enhance shareholder value. Align Partners has requested that Coway announce a revised corporate Value-up Plan reflecting these proposals by January 30, 2026. In the letter, Align Partners assessed Coway’s February 2025 plan as insufficient to address Coway’s persistent undervaluation and urged the Board to incorporate seven measures: (1) clear mid-to-long-term valuation and ROE targets with execution plans; (2) clarified and strengthened target capital structure policy; (3) updated shareholder return policy reflecting both the target capital structure policy and new dividend income tax separation regime; (4) en
Marathon Asset Management Provides Junior Capital Financing to EXALTA Group15.12.2025 15:00:00 CET | Press Release
Marathon Asset Management (“Marathon”), a leading global credit manager with more than $24 billion of assets under management, is pleased to announce the closing of a junior capital financing to EXALTA Group (“EXALTA” or the “Company”), a portfolio company of Montagu. Marathon led the financing that supported the formation of EXALTA through the strategic merger of three Montagu-owned companies including Intech, Resolve Surgical Technologies, and Tyber Medical. The transaction marks one of many successful transactions for Marathon’s European Credit business in the healthcare sector, where the firm has a knowledge-based advantage with a dedicated Healthcare Finance business and specialized medical advisory board providing sector insight to middle market companies. EXALTA is a global leader in orthopaedic contract design and manufacturing for spine, trauma, extremities, sports medicine and enabling technology providing comprehensive solutions to OEMs within the medical technology industry
Aurobay Technologies Expands Digital Transformation Partnership With HCLTech to Boost Manufacturing Excellence and Innovation15.12.2025 14:29:00 CET | Press Release
HCLTech, a leading global technology company, and Aurobay Technologies, a division of Horse Powertrain and a global leader in hybrid and low-emission powertrain solutions, have expanded their digital transformation partnership to support Aurobay’s global growth strategy. The expanded partnership establishes HCLTech as Aurobay Technologies’ trusted partner for managing and optimizing SAP, Siemens Teamcenter PLM software and integration services in Sweden and China. This will unlock cost efficiency, operational resilience and digital innovation across Aurobay’s manufacturing and engineering functions by leveraging HCLTech’s flagship service transformation platform, AI Force. The engagement spans core business functions including SAP operations, engineering systems, integration services and mainframe environments, reinforcing Aurobay’s focus on scale, efficiency and seamless operations across global locations. “Horse Powertrain’s division Aurobay Technologies’ digital transformation conti
Applications Now Open for the 5th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award15.12.2025 14:28:00 CET | Press Release
HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE), announced the opening of applications for the 5th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award, offering USD 1 million in prizes. The award seeks to inspire innovative, clean energy–powered solutions for water production, distribution, storage, desalination and purification, supporting global sustainability efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215897854/en/ HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE) - (Photo: AETOSWire) “Since its establishment, Suqia UAE, launched by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has provided clean water to nearly 15 million people in 37 countries worldwide through sustainable development and humanitarian projects.
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press Release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom